← All trials
NCT05827978
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 17, 2023
- Primary completion
- Jul 10, 2024
- Completion date
- Jul 10, 2024
- First posted
- Apr 25, 2023
- Last posted
- Dec 21, 2023
- Enrollment
- 8400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Moderna TherapeuticsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.